| Literature DB >> 35535905 |
Yang Jiao1, Yue-Tong Sun2, Nai-Fei Chen2, Li-Na Zhou3, Xin Guan4, Jia-Yi Wang4, Wen-Juan Wei4, Chao Han4, Xiao-Lei Jiang2, Ya-Chen Wang4, Wei Zou5, Jing Liu4.
Abstract
Administration of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) is believed to be an effective method for treating neurodevelopmental disorders. In this study, we investigated the possibility of hUC-MSCs treatment of neonatal hypoxic/ischemic brain injury associated with maternal immune activation and the underlying mechanism. We established neonatal rat models of hypoxic/ischemic brain injury by exposing pregnant rats to lipopolysaccharide on day 16 or 17 of pregnancy. Rat offspring were intranasally administered hUC-MSCs on postnatal day 14. We found that polypyrimidine tract-binding protein-1 (PTBP-1) participated in the regulation of lipopolysaccharide-induced maternal immune activation, which led to neonatal hypoxic/ischemic brain injury. Intranasal delivery of hUC-MSCs inhibited PTBP-1 expression, alleviated neonatal brain injury-related inflammation, and regulated the number and function of glial fibrillary acidic protein-positive astrocytes, thereby promoting plastic regeneration of neurons and improving brain function. These findings suggest that hUC-MSCs can effectively promote the repair of neonatal hypoxic/ischemic brain injury related to maternal immune activation through inhibition of PTBP-1 expression and astrocyte activation.Entities:
Keywords: developmental brain disease model; disease-associated astrocytes; intranasal administration; lipopolysaccharide; maternal immune activation; neonatal brain injury; neuroplasticity repair; polypyrimidine tract-binding protein-1; stem cell therapy; umbilical cord-derived mesenchymal stem cells
Year: 2022 PMID: 35535905 PMCID: PMC9120712 DOI: 10.4103/1673-5374.339002
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 6.058